Majority of Americans Approve of Psychedelics to Treat Anxiety, Depression and PTSD
Majority of Americans Approve of Psychedelics to Treat Anxiety, Depression and PTSD A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, reports that nearly...
Study Confirms Cannabis Can Prevent Coronavirus Infections
Study Confirms Cannabis Can Prevent Coronavirus Infections Cannabis has been found to treat a growing number of maladies from depression, anxiety and PTSD. We very excited about a recent study published by researchers at Oregon State University that has, in fact,...
Use of Cannabis in PTSD Treatment of Navy Seals Discussed by Leading Psychologist
Use of Cannabis in PTSD Treatment of Navy Seals Discussed by Leading Psychologist Harvard-trained forensic psychologist Dr. Kara Coe has released an update discussing her innovative use of cannabis as she works Navy SEALs dealing with post-traumatic stress disorder...
Research: CannaboBreast Products Kill Cancer Cells in Patients
Research: CannaboBreast Products Kill Cancer Cells in Patients The composition of cannabinoids and mushrooms in combination with standard chemotherapy improved the effectiveness in killing cancer cells from 10% mortality to 60% mortality New medical research conducted...
Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD
Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. Related: Should You...
CanninPlus with Trading Alerts!
Get advance notice of profitable cannabis & hemp stock trades. Use our machine learning algorithm to start profiting from this explosive industry.
$99 / month after 7-day trial.
Still unsure? Schedule demo at [email protected]
or call 720-254-1374
The Best Cannabis Stocks for 2022
-
Cannin Report Q2 2021
$49.00
-
Cannin Report Q1 2021
$29.00
-
The Cannin Report 2020
$19.00
-
FREE Sample Cannin Report Q1 2020 - Our #1 Stock Pick
$0.00
-
The Cannin Report Q4 2019
$29.00
